As of September 27, 2026, TRex Bio has filed a registration statement (Form S-1) with the SEC to list on the Nasdaq stock exchange under the ticker symbol TRXB, according to a Reuters report dated September 18, 2026. The filing names five underwriters: J.P. Morgan, Evercore ISI, Cantor, Stifel, and Wedbush PacGrow. As of the filing date, no price range, share count, or total deal size had been set. TRex Bio develops immunoregulatory medicines through its proprietary Deep Biology Platform, which maps how tissue regulatory T cells (Tregs) shape inflammation, according to TradingView reporting from September 18, 2026; its lead candidate, TRB-061, a TNFR2 agonist, is in a Phase 1b study for atopic dermatitis. On September 22, 2026, BioSpace reported that the prospectus discloses Eli Lilly has indicated an interest in participating in the offering. Lilly paid TRex Bio $55 million upfront in early 2023, with more than $1.1 billion in potential milestones tied to the TRB-051 program from the same Treg-immunology platform. Track SEC EDGAR and TRex Bio's own statements directly for the price range, share count, and listing date once they are set.
segmara.com publishes educational private-market context and can route limited interest into account-based private follow-up. Public pages do not create an offer, allocation, payment instruction, investment advice, or issuer-affiliated workflow.
Key points
An S-1 is filed, but the terms are not set
TRex Bio filed a Form S-1 registration statement with the SEC to list on the Nasdaq stock exchange under the ticker symbol TRXB, according to a Reuters report dated September 18, 2026.
The filing names five underwriters: J.P. Morgan, Evercore ISI, Cantor, Stifel, and Wedbush PacGrow. As of the filing, no price range, share count, or total deal size had been set. An S-1 filing is a required regulatory step toward a US listing, not confirmation of a specific date or valuation.
Eli Lilly's existing stake in the story
On September 22, 2026, BioSpace reported that TRex Bio's IPO prospectus discloses that Eli Lilly has indicated an interest in participating in the offering.
That interest builds on an existing partnership. Lilly paid TRex Bio $55 million upfront in early 2023, with more than $1.1 billion in potential milestones tied to the TRB-051 program, which comes out of TRex Bio's Deep Biology Treg-immunology platform. An indication of interest from a partner is not a commitment to buy shares at a set price, and it does not by itself set the IPO's timing or size.
What TRex Bio does
TRex Bio develops immunoregulatory medicines through its proprietary Deep Biology Platform, which maps how tissue regulatory T cells (Tregs) shape inflammation, according to TradingView reporting from September 18, 2026.
Its lead candidate, TRB-061, a TNFR2 agonist, is in a Phase 1b study for atopic dermatitis. SEC EDGAR covers only US filings; track TRex Bio's own statements and its S-1 amendments there for the price range, share count, and any listing date once they are set.
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
Metric
Value
Context
Canonical route
/blog/when-will-trex-bio-ipo
Stable URL path for AI and search extraction.
Article title
When Will TRex Bio IPO? Filed for Nasdaq as TRXB, No Price Set
Main page topic.
Attached public sources
3
Number of citation links rendered at the bottom of the article.
Segmara listed companies
51
Live private-company listings in the public catalogue.
Priced listings
37
Catalogue listings with visible indicative or direct marks.
Request-quote listings
14
Catalogue listings where a public price is intentionally not invented.
Data fingerprint chart
Catalogue breadth100%
51 public listings
Visible pricing coverage72%
37 of 51 listings show a mark
Source depth58%
3 source links
Stage
Timing
Price / valuation signal
Interpretation
Chart metric
Score
Interpretation
Catalogue breadth
100 / 100
51 public listings
Visible pricing coverage
72 / 100
37 of 51 listings show a mark
Source depth
58 / 100
3 source links
Analytical lens
Search intent
The search behind 'When Will TRex Bio IPO? Filed for Nasdaq as TRXB, No Price Set' is an access-intent query. People want to know where they can start interest in TRex Bio private-market exposure without needing a private equity relationship, fund connection, or insider network.
Access path
segmara.com turns that search into a simple path: browse the listing, create an account, choose the company, and start the private-share inquiry. Final pricing and availability still depend on the route, but the starting point is public and straightforward.
Segmara role
Segmara works as a private-market access layer for interested visitors. The site helps visitors discover private markets categories that were previously hard to research and moves them into an account-based inquiry in a few steps.
Private-share path map
From gatekept to accessible
BrowseRetail investor finds a private-company listing.
AccountBuyer creates one Segmara account.
RequestBuyer starts the private-share purchase request.
CloseAvailability, price, approvals, and final terms are handled privately.
Access-friction chart
Illustrative map of where the old private-market process was hardest and where Segmara makes the starting point easier.
Old-market frictionPrivate networks and institutional access
Segmara discoveryPublic listings retail buyers can browse
Account workflowOne account to start the purchase request
Private closeFinal terms handled after buyer interest
How private-share access starts on Segmara
TRex Bio filed an S-1 to list on Nasdaq under ticker TRXB on September 18, 2026, according to Reuters. The underwriters are J.P. Morgan, Evercore ISI, Cantor, Stifel, and Wedbush PacGrow, with no price range, share count, or deal size set.
BioSpace reported on September 22, 2026 that TRex Bio's prospectus discloses Eli Lilly has indicated an interest in participating in the offering. Lilly paid TRex Bio $55 million upfront in early 2023, with over $1.1 billion in potential milestones tied to the TRB-051 program.
TRex Bio's lead candidate, TRB-061, a TNFR2 agonist developed on its Deep Biology Platform that maps how tissue regulatory T cells (Tregs) shape inflammation, is in a Phase 1b study for atopic dermatitis, according to TradingView reporting from September 18, 2026.
Risk notes
Rumor risk: unofficial dates, valuations, or funding details circulating on social media or forums are frequently wrong or outdated and should not be treated as confirmation of anything.
Illiquidity risk: any private-market interest, indicative marks, or pre-IPO share arrangements in a company that has not listed can be difficult to exit and may not reflect a tradable price.
Timing risk: a company can pause, restart, or abandon IPO preparation at any stage, including after a confidential or public filing, so no step before pricing guarantees a listing.
Free: every article, the IPO calendar and the weekly IPOs page. Pro: same-day filing alerts and the weekly brief on all 99 companies, with a 7-day free trial, then $15 a month. Research only, no share sales.
Can retail investors track private-company shares on Segmara?
Yes. Visitors can start with the free TRex Bio tracker using email only, then decide whether a private follow-up makes sense. Availability, eligibility, pricing, allocation, transfer approval, documents, and final terms can still vary by route.
Why was this market historically hard for retail investors to reach?
Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes the starting point simpler: visitors can follow named private-company interest before any account, document upload, or payment step.
What is the easiest next step?
Open the free TRex Bio tracker first. It is email-only and keeps the public step narrow while final availability, pricing, eligibility, and terms are handled only through private follow-up.
Has TRex Bio confirmed an IPO date?
No. TRex Bio filed an S-1 on September 18, 2026 to list on Nasdaq under ticker TRXB, but as of that filing no price range, share count, deal size, or specific listing date had been set, according to Reuters.
What is TRex Bio's ticker and exchange?
TRex Bio has filed to list on the Nasdaq stock exchange under the ticker symbol TRXB, according to the September 18, 2026 S-1 reported by Reuters.
Is Eli Lilly involved in TRex Bio's IPO?
BioSpace reported on September 22, 2026 that TRex Bio's prospectus discloses Eli Lilly has indicated an interest in participating in the offering. Lilly and TRex Bio already have a partnership: Lilly paid $55 million upfront in early 2023, with over $1.1 billion in potential milestones tied to the TRB-051 program.
Can I buy TRex Bio shares before the IPO?
Not through Segmara. Segmara is a research resource and does not sell, broker, or arrange the purchase of TRex Bio shares, before or after any IPO.
Next step
Track private-market prices free.
If this article helped explain TRex Bio, start with the free tracker: indicative pre-IPO marks by email. No card, no documents, no brokerage account, and no allocation promise.
When a full account makes sense, Segmara can route limited interest into an account-based private follow-up. Availability, pricing, eligibility, allocation, transfer approval, liquidity, and final terms can vary by company and route.